Today: 11 November 2025
Subscribe
Browse Category

Healthcare News 15 October 2025 - 6 November 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly stock today: drivers, numbers, and what to watch for next. Key takeaways (Nov 6, 2025) Eli Lilly stock today: quote & range As of this afternoon, LLY traded near $935.89, up about 1.1%, with today’s range $916.37–$949.90 and a 52‑week range $624.00–$955.43 (values delayed up to 15 minutes). Reuters 1) The White House’s obesity‑drug deal: lower prices, broader access President Donald Trump announced deals with Eli Lilly and Novo Nordisk to reduce U.S. costs and expand coverage for in‑demand weight‑loss medicines. The plan includes Medicare coverage for obesity treatment, expected to carry $50 monthly copays for eligible beneficiaries,
6 November 2025
 ·  ·  ·  ·  ·  · 
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers (HIMS) Stock Soars on Subscriber Surge and GLP-1 Deal Buzz – Nov 2025 Update

Current Stock Price (Nov 3, 2025) Hims & Hers Health’s stock (NYSE: HIMS) closed on Nov 3, 2025 at $44.39, down about 2.3% for the day stockanalysis.com. This modest dip came amid a broader mixed market and ahead of the company’s earnings release after the bell. However, immediately following its Q3 earnings report that evening, HIMS shares jumped roughly 6% in after-hours trading, climbing to around $46.70 investing.com. The post-market pop was driven by upbeat revenue and subscriber numbers (more on that below), signaling renewed investor optimism. Even after recent volatility, HIMS stock has had a stellar year. At ~$44–$47,
4 November 2025
 ·  ·  ·  ·  · 
TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseases gurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S. gurufocus.com. The company’s strategy centers on leveraging its expertise in B-cell biology to address both autoimmune disorders and B-cell cancers. Briumvi – A Breakthrough in Multiple Sclerosis Therapy Briumvi (ublituximab-xiiy) is TG’s flagship drug, approved by the FDA in December 2022 for adults with relapsing forms of multiple sclerosis
3 November 2025
 ·  ·  ·  ·  · 
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Strong Q3 Earnings Propel Stock Higher Guardant’s latest quarterly report blew past Wall Street’s expectations, sparking a sharp rally in its shares. For Q3 2025, revenue was $265.2 million, a 39% jump from a year ago and well above the ~$235 million analysts had forecast investing.com. On an adjusted basis, Guardant lost $0.39 per share, much better than the roughly $0.79 loss expected. Management immediately lifted the full-year sales outlook to $965–970 million (about 31% growth) investors.guardanthealth.com, up from $915–925M previously. As a result, GH stock jumped nearly 30% in morning trading on Oct. 30 (to about $94, from ~$72
30 October 2025
 ·  ·  ·  ·  · 
VSee Health (VSEE) Stock Rockets 75% on $10M Hospital Teleradiology Deal – Is This Telehealth’s Next Big Winner?

VSee Health (VSEE) Skyrockets 200% on Federal Telehealth Approval – Will the Surge Last?

Stock soars on federal approval, then steadies at new highs VSee Health’s stock (NASDAQ: VSEE) has experienced a whirlwind rally over the past two trading days. On October 28, shares of the telehealth upstart skyrocketed on news of a coveted federal security certification. The price leapt from just $0.62 at Monday’s close to as high as $2.52 during Tuesday’s intraday trading – a ~4× gain ts2.tech. Extraordinary trading volume accompanied the spike, with over 156 million shares changing hands (versus under 2 million on an average day) ts2.tech. Such a surge is remarkable, especially for a micro-cap stock, and prompted
29 October 2025
 ·  ·  ·  ·  · 
UnitedHealth Stock Rallies to $364 – Will UNH’s 2025 Comeback Last or Fade?

UnitedHealth Stock Rallies to $364 – Will UNH’s 2025 Comeback Last or Fade?

Stock Price Snapshot: October 2025 Rebound UnitedHealth stock has seen volatile swings in 2025, but recent weeks brought a measure of relief. As of Oct. 21, shares trade around $364, up from the lows hit earlier in the year. On Monday (Oct. 20), UNH jumped +2.21% to close at $364.48 investing.com, recovering from a mid-month dip. Over the past week the stock oscillated in the mid-$350s to $360s, essentially flat to slightly higher overall investing.com. Despite this stabilization, UnitedHealth remains deep in the red for 2025. The stock is still down roughly 30–35% year-to-date (depending on the reference point) ts2.tech,
21 October 2025
 ·  ·  ·  ·  · 
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to Beam’s lead programs (BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency) globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside. Beam’s stock jumped sharply after the FDA awarded priority designations to its gene-editing therapies. On Oct 20,
21 October 2025
 ·  ·  ·  ·  · 
DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

Stock Surges on SteadyMD Acquisition DocGo’s shares jumped more than 34% in after-hours trading on Oct. 20, 2025, after the company announced it would acquire SteadyMD, a virtual care platform. According to an Investing.com report, DocGo stock “surged 34.6% in after-hours trading Monday following the company’s announcement that it has acquired virtual care platform SteadyMD” m.uk.investing.com. The acquisition was disclosed on Monday, Oct. 20, and a conference call to discuss it was scheduled for Oct. 21. SteadyMD brings a nationwide telehealth network (600+ clinicians serving ~3 million patients in 2025) to DocGo’s existing mobile health and ambulance services citybiz.co m.uk.investing.com.
21 October 2025
 ·  ·  ·  ·  · 
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81 stockanalysis.com stockanalysis.com. That rally marked a new 2025 high for the biotech stalwart and brings its year-to-date gain to roughly 45–47% ts2.tech. By comparison, the Nasdaq Biotechnology Index is up only in the single digits over the same period ts2.tech. The recent jump – adding billions to Gilead’s market cap – reflects
18 October 2025
 ·  ·  ·  ·  · 
INVO Fertility (IVF) Stock’s Wild 90% Surge Amid IVF Boom – What’s Behind the Frenzy?

INVO Fertility (IVF) Stock’s Wild 90% Surge Amid IVF Boom – What’s Behind the Frenzy?

Stock Price Surge and Aftermath INVO Fertility’s stock took Wall Street by surprise this week with a massive one-day surge. On October 16, shares of the micro-cap fertility clinic operator opened around $0.75 and skyrocketed nearly 90% by day’s end, closing at approximately $1.43 ts2.tech. Intra-day, the price briefly hit $2+ per share, a huge jump from the prior day’s close under $0.80 ts2.tech. To put this in perspective, such a single-day leap is virtually unheard of for most stocks – even in the volatile biotech space – and far outpaced broader market moves. Trading volume spiked astronomically during the
17 October 2025
 ·  ·  ·  ·  · 
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from January levels reuters.com reuters.com and miles below the late-2024 peak (when Novo’s market cap neared $650 B) reuters.com reuters.com. What happened? In short, the once-unbounded GLP-1 weight-loss boom has hit reality. Several factors have converged to deflate Novo’s valuation. Competition has
17 October 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

Lawsuit Outcome and Court Ruling Humana (the second‐largest Medicare Advantage insurer) sued CMS in July after its star rating unexpectedly plunged. The insurer argued that CMS unfairly flagged three interpreter calls as failures (with no callback allowed), causing a 4.5-to-3.5 star drop reuters.com healthcaredive.com. On Oct. 14, U.S. District Judge Reed O’Connor (Northern Texas) rejected Humana’s arguments reuters.com. He found that CMS had acted “in accordance with its guidelines” and did not act arbitrarily fiercehealthcare.com. In particular, the judge upheld CMS’s no-callbacks policy for those language-line test calls as lawful healthcaredive.com. The case was dismissed “with prejudice,” meaning Humana can’t
15 October 2025
 ·  ·  ·  ·  · 
1 2 3
Go toTop